Landmark Study Investigating Novel Alzheimer’s Biomarkers Advances to Data Analysis Stage
14 juin 2023 06h00 HE
|
Global Alzheimer's Platform Foundation
WASHINGTON, DC, June 14, 2023 (GLOBE NEWSWIRE) -- Up to 50 percent of people in the U.S. with Alzheimer’s receive an imprecise or inaccurate diagnosis of their cognitive condition. The tools...
Global Alzheimer’s Platform Foundation (GAP) President Blasts CMS’ “Unprecedented and Pernicious” Discrimination Against People with Alzheimer’s Disease
23 févr. 2023 08h51 HE
|
Global Alzheimer's Platform Foundation
Washington, D.C., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Statement by Global Alzheimer’s Platform Foundation® President John Dwyer: “Once again, the Centers for Medicare and Medicaid Services (CMS) has...
Clinical Trial Volunteers Honored with National Citizen Scientist Awards for Participating in Research
23 févr. 2023 07h00 HE
|
Global Alzheimer's Platform Foundation
WASHINGTON, DC, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Today, the Global Alzheimer’s Platform Foundation (GAP) proudly announced the recipients of the 2022 National Citizen Scientist Awards®. GAP’s...
Global Alzheimer’s Platform Foundation Statement on FDA Accelerated Approval of Lecanemab
06 janv. 2023 14h25 HE
|
Global Alzheimer's Platform Foundation
Washington, D.C., Jan. 06, 2023 (GLOBE NEWSWIRE) -- "We applaud the Food and Drug Administration (FDA)’s decision to grant accelerated approval to lecanemab, a treatment that offers millions of...
First of its Kind Head-to-Head Study Comparing Leading Biomarkers for Detecting Alzheimer’s Disease Closes With Unprecedented Representation from Underrepresented Populations
15 nov. 2022 06h00 HE
|
Global Alzheimer's Platform Foundation
WASHINGTON, DC, Nov. 15, 2022 (GLOBE NEWSWIRE) -- In 18 months, the Global Alzheimer’s Platform Foundation (GAP) recruited more than 1,000 participants to enroll in the first-ever head-to-head study...
Global Alzheimer’s Platform Foundation (GAP) Celebrates Lecanemab’s Positive Clinical Trial Results
28 sept. 2022 12h09 HE
|
Global Alzheimer's Platform Foundation
WASHINGTON, DC, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Today, the Global Alzheimer’s Platform Foundation (GAP) applauds and welcomes the Phase 3 study results on lecanemab for treating Alzheimer’s...
Global Alzheimer’s Platform Foundation and WCG collaborate to improve access to clinical trials for traditionally underrepresented communities
01 août 2022 08h00 HE
|
Global Alzheimer's Platform Foundation
WASHINGTON, DC, Aug. 01, 2022 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) and WCG announced a joint program today that will increase the availability of educational...
GAP Takes Alzheimer’s Clinical Trials On the Road to Remove Barriers to Access
14 juil. 2022 14h36 HE
|
Global Alzheimer's Platform Foundation
WASHINGTON, DC, July 14, 2022 (GLOBE NEWSWIRE) -- Today, Global Alzheimer's Platform Foundation (GAP) President John Dwyer announced the launch of a new mobile health site, which is hitting the road...